NO20074188L - Prosess for fremstilling av montelukast og mellomprodukter for det - Google Patents

Prosess for fremstilling av montelukast og mellomprodukter for det

Info

Publication number
NO20074188L
NO20074188L NO20074188A NO20074188A NO20074188L NO 20074188 L NO20074188 L NO 20074188L NO 20074188 A NO20074188 A NO 20074188A NO 20074188 A NO20074188 A NO 20074188A NO 20074188 L NO20074188 L NO 20074188L
Authority
NO
Norway
Prior art keywords
montelukast
intermediates
manufacturing
compound
formula
Prior art date
Application number
NO20074188A
Other languages
English (en)
Inventor
Arjanne Overeem
Lambertus Thijs
Petr Benovsky
Jakub Castulik
Jie Zhu
Petr Bartos
Radomir Skoumal
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20074188L publication Critical patent/NO20074188L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/75—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En prosess for å lage montelukast, en farmasøytisk nyttig forbindelse av den følgende formelen og salter derav: anvendelse av en forbindelse av en formel(11) er tilveiebrakt
NO20074188A 2005-11-18 2007-08-15 Prosess for fremstilling av montelukast og mellomprodukter for det NO20074188L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73775205P 2005-11-18 2005-11-18
US79442906P 2006-04-24 2006-04-24
US82438206P 2006-09-01 2006-09-01
PCT/EP2006/011127 WO2007057225A2 (en) 2005-11-18 2006-11-20 Process for making montelukast and intermediates therefor

Publications (1)

Publication Number Publication Date
NO20074188L true NO20074188L (no) 2008-08-13

Family

ID=37685804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074188A NO20074188L (no) 2005-11-18 2007-08-15 Prosess for fremstilling av montelukast og mellomprodukter for det

Country Status (12)

Country Link
US (5) US7476748B2 (no)
EP (3) EP1954679B1 (no)
JP (1) JP2009515922A (no)
AR (3) AR056815A1 (no)
AT (1) ATE497493T1 (no)
AU (3) AU2006314728A1 (no)
CA (3) CA2629840A1 (no)
DE (1) DE602006019979D1 (no)
IL (1) IL185129A0 (no)
NO (1) NO20074188L (no)
PT (1) PT1954679E (no)
WO (3) WO2007057227A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146809A1 (en) * 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
CA2608369A1 (en) 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Purification of montelukast
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
EP2014650A1 (en) * 2007-07-13 2009-01-14 Lonza Ag Process and intermediate for the production of an intermediate in the production of montelukast
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
TWI450275B (zh) * 2010-05-19 2014-08-21 Wistron Corp 可提升寫入保護之記憶體系統及相關方法
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) * 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU593278B2 (en) * 1985-08-06 1990-02-08 Boehringer Mannheim Italia S.P.A. Pharmaceutically active 2-thiomethyl-substituted-1,4- dihydropyridines
CA2038178A1 (en) 1990-04-05 1991-10-06 Carl C. Greco Niobium alkoxyalkoxides and process for formation
HUT61980A (en) * 1990-10-12 1993-03-29 Merck Frosst Canada Inc Process for producing saturated hydroxyalkylquinoline acids and pharmaceutical compositions comprising such compounds as active ingredient
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
ES2114882T3 (es) 1990-10-12 1998-06-16 Merck Frosst Canada Inc Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
CN1420113A (zh) 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
CA2541994A1 (en) 2003-10-10 2005-05-06 Arjanne Overeem Solid-state montelukast
KR20060117356A (ko) * 2004-01-30 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 유리산 다형체
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US20090143590A1 (en) * 2004-07-19 2009-06-04 Matrix Laboratories Ltd. Process for the Preparation of Montelukast and its Salts
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST

Also Published As

Publication number Publication date
CA2598093A1 (en) 2007-05-24
AU2006314728A1 (en) 2007-05-24
WO2007057225A3 (en) 2007-07-26
WO2007057228A1 (en) 2007-05-24
US20070135642A1 (en) 2007-06-14
EP1960362A1 (en) 2008-08-27
AR057908A1 (es) 2007-12-26
EP1954679B1 (en) 2011-02-02
WO2007057225A2 (en) 2007-05-24
US20090093636A1 (en) 2009-04-09
US20070135643A1 (en) 2007-06-14
AR057909A1 (es) 2007-12-26
US7476748B2 (en) 2009-01-13
ATE497493T1 (de) 2011-02-15
IL185129A0 (en) 2007-12-03
AR056815A1 (es) 2007-10-24
AU2006314729A1 (en) 2007-05-24
DE602006019979D1 (de) 2011-03-17
CA2629834A1 (en) 2007-05-24
JP2009515922A (ja) 2009-04-16
AU2006314726A1 (en) 2007-05-24
WO2007057227A1 (en) 2007-05-24
US7601741B2 (en) 2009-10-13
EP1954679A1 (en) 2008-08-13
US20100099879A1 (en) 2010-04-22
US20070135480A1 (en) 2007-06-14
CA2629840A1 (en) 2007-05-24
US7786138B2 (en) 2010-08-31
EP1948610A2 (en) 2008-07-30
PT1954679E (pt) 2011-05-05

Similar Documents

Publication Publication Date Title
NO20074188L (no) Prosess for fremstilling av montelukast og mellomprodukter for det
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
NO20054852L (no) GFAT inhibitorer
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
MY141194A (en) Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
NO20074642L (no) Fremgangsmate for a lage trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
ME01992B (me) Jedinjenje diarilhidantoina
NO20050921L (no) Nye fysiologisk aktive substanser
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
EA200901039A1 (ru) Способ получения производного бензимидазола
TW200728307A (en) Novel spirochromanone derivatives
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
TN2009000484A1 (en) Substituted oxazolidinones and the use thereof
NO20082096L (no) Azaindol-2-karboksamidderivativer
MY149058A (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre
NO20062599L (no) Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav
NO20076000L (no) Aminosyrederivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application